Comparison of two routes of administration of a cationic liposome formulation for a prophylactic DC vaccination in a murine melanoma model.

Abstract

Dendritic cell (DC) vaccination can be achieved via straight loading of vaccine into DCs ex vivo or administration to DCs in vivo. However, there is no certain consensus on which approach is preferable, and each strategy has its advantages and disadvantages, which affect the efficacy and safety of vaccines. It will also be more complicated when a vaccine delivery system is included. In this study, the efficacy of ex vivo pulsed DC-based vaccine compared with in vivo subcutaneous administration of a cationic liposomes (CLs) formulation containing gp100 antigen (gp100-CLs) was evaluated in a murine melanoma model. In combination with an anti-PD-1 antibody, the ex vivo approach of gp100-CLs yielded a significant (P < 0.01) increase in the number of antigen-specific tumors infiltrated lymphocytes (TILs) with a significant upregulation of IFN-γ (P < 0.0001) and PD-1 (P < 0.0001) expression level. They also dampened the function of immunosuppressive regulatory T cells (Tregs) via significant downregulation of IL-10 and TGF-β (P < 0.0001) expression level compared to in vivo approach in the tumor microenvironment (TME). Furthermore, prophylactic immunization with gp100-CLs pulsed DCs ex vivo delayed tumor growth and induced the survival benefit over in vivo immunization. Collectively, the ex vivo DC-based vaccination pulsed with gp100 encapsulated in liposomes synergizes with anti-PD-1 antibody and represents a preferable approach against melanoma.

• Authors: Mona Yazdani, Amin Reza Nikpoor, Zahra Gholizadeh, Nema Mohamadian Roshan, Alexander Seifalian, Mahmoud Reza Jaafari, Ali Badiee
• Journal: International immunopharmacology (Int Immunopharmacol) Vol. 98 Pg. 107833 (Sep 2021) ISSN: 1878-1705 [Electronic] Netherlands
• PMID: 34352472 (Publication Type: Comparative Study, Journal Article)
• Copyright: Copyright © 2021 Elsevier B.V. All rights reserved.

Chemical References

• Antineoplastic Agents, Immunological
• Cancer Vaccines
• Liposomes
• Programmed Cell Death 1 Receptor
• gp100 Melanoma Antigen

Topics

• Animals
• Antigen Presentation
• Antineoplastic Agents, Immunological (pharmacology, therapeutic use)
• Cancer Vaccines (immunology)
• Combined Modality Therapy
• Dendritic Cells (immunology, transplantation)
• Disease Models, Animal
• Drug Administration Routes
• Humans
• Immunotherapy, Adoptive (methods)
• Liposomes (chemical synthesis, metabolism)
• Lymphocytes, Tumor-Infiltrating (immunology)
• Melanoma (immunology, therapy)
• Melanoma, Experimental
• Mice
• Mice, Inbred C57BL
• Programmed Cell Death 1 Receptor (antagonists & inhibitors)
• Skin Neoplasms (immunology, therapy)
• T-Lymphocytes, Regulatory (immunology)
• Vaccination
• gp100 Melanoma Antigen (metabolism)